Active specific immunotherapy of established micrometastases with BCG plus tumor cell vaccines: Effective treatment of BCG side effects with isoniazid

Abstract

Intradermal vaccinations with Bacillus Calrnette-Gutin (BCG) and viable but nontumorigenic syngeneic hepatocarcinoma cell vaccines were used successfully to treat micrometastatic disease experimentally induced in inbred guinea pigs at 100 times the minimal lethal dose. Several complications have been associated with the use of viable BCC organisms in the treatment of cancer patients and, in this animal model, intradermal administration of BCG uniformly results in severe ulceration and eschar formation at the injection sites leading to secondary microbial invasion and regional lymphadenopathy. We now report the use of isoniazid (Nydrazid") as part of an active specific immunization regimen. Incorporation of isoniazid into the immunization procedure for two weeks alleviates or reduces the side effects of BCG infection. Moreover, with proper consideration of BCC dosage, isoniazid does not impair the efficacy of the BCC plus tumor cell vaccines. Cancer 49659-664, 1982. REVIOUS STUDIES from our laboratory have de

Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!

“…The decision to go further from mouse to man was based on two considerations: (i) the urgent need in the clinic for a new post-operative strategy against metastases and (ii) the development in the USA of an autologous live cell tumor vaccine mixed with Bacillus Calmette Guérin (BCG) by Hanna and colleagues [25,26]. …”

Vaccine therapy for colon cancer

“…A series of studies in the guinea pig line 10 hepatocarcinoma model [1][2][3][4][5][6] demonstrated that BCG mixed with autologous tumor cells can induce systemic immunity capable of eliminating a limited disseminated tumor burden when the vaccine is carefully controlled for quality variables. These include the number of tumor cells, ratio of viable BCG organisms to tumor cells, viability of the tumor cells, and the vaccination regimen.…”